Logo Geneseeq
  • Services
    • Genomic Testing
      • Companion Diagnostic Test
      • Laboratory Developed Tests (LDT)
        • Solid Tumors
        • Hematologic Malignancies
        • Hereditary Cancers
        • Minimal Residual Disease
    • Research Services
      • Platforms
      • DNA Sequencing
      • RNA Sequencing
      • Other Services
  • Technology
    • Our Technology
    • Publications
  • Partnerships
  • About Us
    • What is Precision Oncology?
    • Our Company
    • Our Team
    • Certificates & Accreditation
  • News
  • Join Us
  • Contact Us
  • Ch|中文
  • Search

November 15, 2022

Geneseeq Publishes Promising Early Lung Cancer Detection Results in AJRCCM

by Geneseeq

November 3, 2022

Geneseeq study evaluates the clinical value of cell-free DNA 5’-end motif profile in the prediction of pathological complete response for LARC patients after neoadjuvant chemoradiotherapy

by Geneseeq

October 12, 2022

Interesting findings on ctDNA-based MRD detection in patients with resectable non-small cell lung cancer by Geneseeq

by Geneseeq

July 19, 2022

Geneseeq, Brazilian Hospital Partner on Co-establishment of In-house NGS Lab

by Geneseeq

November 8, 2021

Geneseeq collaborates on research identifying predictive biomarkers for guiding personalized adjuvant treatment in resected EGFR-positive non-small cell lung cancer

by Geneseeq

June 17, 2021

Geneseeq Joins Integrated DNA Technologies (IDT) Align Program

by Geneseeq

Logo Geneseeq

1-647-255-1076
1-800-362-0325
info.toronto@geneseeq.com

Quick Links
  • Services
  • Technology
  • News
  • About Us
Connect
  • Partnerships
  • Join us
  • Contact us
Privacy
  • Privacy Policy
  • Terms of Use
Headquarters

101 College Street
Suite 200, MaRS Centre
South Tower
Toronto, Ontario, M5G 1L7
Canada

© 2022 Geneseeq Technology Inc. | A Precision Oncology Company. All rights reserved

Privacy Preference Center

Privacy Preferences